Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Shankles, B., Harrop, K., Drachman, J. G. AMER SOC HEMATOLOGY. 2006: 209A
View details for Web of Science ID 000242440000696